Balance Sheet
Cash Flow Statement
AmortizationAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Change in Inventory (2020 - 2025)

Historic Change in Inventory for Legend Biotech (LEGN) over the last 6 years, with Q3 2025 value amounting to $5.4 million.

  • Legend Biotech's Change in Inventory rose 20574.69% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.9 million, marking a year-over-year increase of 5280.3%. This contributed to the annual value of -$17.2 million for FY2024, which is 3543.21% down from last year.
  • Legend Biotech's Change in Inventory amounted to $5.4 million in Q3 2025, which was up 20574.69% from -$2.8 million recorded in Q2 2025.
  • Legend Biotech's Change in Inventory's 5-year high stood at $5.4 million during Q3 2025, with a 5-year trough of -$8.6 million in Q4 2022.
  • Its 5-year average for Change in Inventory is -$2.5 million, with a median of -$2.8 million in 2025.
  • In the last 5 years, Legend Biotech's Change in Inventory tumbled by 738260.87% in 2022 and then soared by 20574.69% in 2025.
  • Quarter analysis of 5 years shows Legend Biotech's Change in Inventory stood at -$115000.0 in 2021, then crashed by 7382.61% to -$8.6 million in 2022, then skyrocketed by 56.98% to -$3.7 million in 2023, then plummeted by 69.23% to -$6.3 million in 2024, then skyrocketed by 185.76% to $5.4 million in 2025.
  • Its Change in Inventory was $5.4 million in Q3 2025, compared to -$2.8 million in Q2 2025 and -$3.2 million in Q1 2025.